Apr 202 min read

New Positive Data on Nattokinase

By Peter A. McCullough, MD, MPH

https://petermcculloughmd.substack.com/p/nattokinase-dissolves-fibrinaloid?utm_source=post-email-title&publication_id=1119676&post_id=143587364&utm_campaign=email-post-title&isFreemail=true&r=1bz278&triedRedirect=true&utm_medium=email

Post-acute sequelae after SARS-CoV-2 infection (long COVID) and after COVID-19 vaccination are characterized by micro-blood clotting. The work of Scheim et al. suggests that most syndromes in both cases are due to Spike protein-mediated hemagglutination and then the development of small clots that serve the major organs in the body. Xi et al. demonstrated an increased risk for microclots visualized in retinal arteries and veins in the COVID-19 vaccinated.

Grixti et al . point out that nattokinase has quickly become part of the community standard of care for post-acute sequelae, as proposed in McCullough Protocol Base Spike Detoxification. They demonstrated that recombinant Nattokinase was fibrinolytic in a lab preparation of fibrinoid microclots, that is, coagulation initiated with fibrinogen, thrombin, and lipopolysaccharide.

doi: https://doi.org/10.1101/2024.04.06.588397

As you can see, the effect was dose-related. This suggests even greater biological plausibility that Nattokinase can indeed dissolve microclots. The next sets of experiments should test microclots induced by Spike protein, thrombin, and fibrinogen. The clinical community has a long way to go in translating these results from bench to bedside. There is a great need for dose-ranging studies with Nattokinase in humans to study fibrinolysis and bleeding risks. In the meantime, these data are reassuring that we are on the right track with Nattokinase broadly, empirically used in patients with post-acute sequelae after SARS-CoV-2 infection (long COVID) and after COVID-19 vaccination.